Imperial Innovations is focused on commercialising leading UK academic research sourced from the ‘golden triangle’ formed between Cambridge, Oxford and London.
This area is home to many groundbreaking technology companies through its proximity to some of the world’s leading research intensive universities.
In addition to our relationship with Imperial, we also work closely with the academic communities associated with the University of Cambridge, the University of Oxford and University College London. This can include working with the technology transfer organisations of those universities, or directly sourcing investment opportunities arising from early-stage companies and research institutions within the golden triangle.
These latter relationships are informal and collaborative and draw on the strength and experience of Imperial Innovations’ staff and networks.
As at 31 January 2014, 11 of Innovations’ top 30 portfolio companies by value were associated with academic research undertaken outside Imperial College London.
Investment in London
Innovations has proprietary access to intellectual property developed at Imperial College London. We have a deep and embedded relationship with the College and its academics, and many of our leading investments have originated from research undertaken at Imperial.
Within London, we also have a good relationship with University College London, through it technology transfer office, UCLB.
Innovations has a productive collaboration in place with Cambridge Enterprise, the spinout equity management organisation for the University of Cambridge. We have made a number of investments in businesses arising from academic research undertaken around Cambridge, and have identified particular strengths in the areas of Therapeutics and ICT/Digital.
Innovations has access to later-stage Oxford companies through its collaboration with Oxford Spinout Equity Management, which provides spinout equity management services to Oxford University. We have made a number of investments in Oxford companies, including leading a significant Series G funding round for Oxford Immunotec, a diagnostics platform company which has since floated on NASDAQ.